Therapeutic options in treatment-resistant depression

References

• Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53:649–59.
   PubMed Web of Science ®Google Scholar
• Nemeroff CB. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res. 2007;41:189–206.
   PubMed Web of Science ®Google Scholar
• Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19:179–200.
   PubMed Web of Science ®Google Scholar
• Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, . The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002; 63:963–71.
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Birnbaum HG, Kidolezi Y, Subramanian G, Khan SA, Stensland MD. Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr Med Res Opin. 2010;26:2475–84.
   PubMed Web of Science ®Google Scholar
• Fostick L, Silberman A, Beckman M, Spivak B, Amital D. The economic impact of depression: resistance or severity? Eur Neuropsychopharmacol. 2010;20:671–5.
   PubMed Web of Science ®Google Scholar
• Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry. 2005;66 Suppl 8:5–12.
   PubMed Web of Science ®Google Scholar
• Pacchiarotti I, Mazzarini L, Colom F, Sanchez-Moreno J, Girardi P, Kotzalidis GD, . Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr Scand. 2009;120:429–40.
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry. 2001;62 Suppl 16:18–25.
   Web of Science ®Google Scholar
• Mendlewicz J, Massat I, Linotte S, Kasper S, Konstantinidis A, Lecrubier Y, ; Group for the Study of Resistant Depression (GSRD). Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. Int Clin Psychopharmacol. 2010;25:297–301.
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression? Biol Psychiatry. 2003;53: 640–8.
   PubMed Web of Science ®Google Scholar
• O'Reardon JP. Pharmacologic and therapeutic strategies in treatment-resistant depression. Introduction and clinical presentations. CNS Spectr. 2009;14(3 Suppl 4):4–6.
   PubMed Web of Science ®Google Scholar
• Serretti A, Mandelli L. The genetics of bipolar disorder: genome ‘hot regions’, genes, new potential candidates and future directions. Mol Psychiatry. 2008;13:742–71.
   PubMed Web of Science ®Google Scholar
• Howland RH, Rush AJ, Wisniewski SR, Trivedi MH, Warden D, Fava M, . Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. Drug Alcohol Depend. 2009;99:248–60.
   PubMed Web of Science ®Google Scholar
• Rane LJ, Fekadu A, Wooderson S, Poon L, Markopoulou K, Cleare AJ. Discrepancy between subjective and objective severity in treatment-resistant depression: prediction of treatment outcome. J Psychiatr Res. 2010;44:1082–7.
   PubMed Web of Science ®Google Scholar
• Amital D, Fostick L, Silberman A, Beckman M, Spivak B. Serious life events among resistant and non-resistant MDD patients. J Affect Disord. 2008;110:260–4.
   PubMed Web of Science ®Google Scholar
• Krishnan KR. Comorbidity and depression treatment. Biol Psychiatry. 2003;53:701–6.
   PubMedGoogle Scholar
• Correa R, Akiskal H, Gilmer W, Nierenberg AA, Trivedi M, Zisook S. Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression? J Affect Disord. 2010;127:10–18.
   PubMed Web of Science ®Google Scholar
• Lee MS, Lee HY, Kang SG, Yang J, Ahn H, Rhee M, . Variables influencing antidepressant medication adherence for treating outpatients with depressive disorders. J Affect Disord. 2010;123:216–21.
   PubMed Web of Science ®Google Scholar
• Colom F, Vieta E, Martinez-Aran A, Reinares M, Benabarre A, Gasto C. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry. 2000;61:549–55.
   PubMedGoogle Scholar
• Fekadu A, Wooderson SC, Markopoulo K, Donaldson C, Papadopoulos A, Cleare AJ. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord. 2009;116:4–11.
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry. 1990;51 Suppl:39–47.
   PubMedGoogle Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
   PubMed Web of Science ®Google Scholar
• Dunner DL, Rush AJ, Russell JM, Burke M, Woodard S, Wingard P, . Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry. 2006;67:688–95.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, . Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163:1905–17.
   PubMed Web of Science ®Google Scholar
• Shergill SS, Robertson MM, Stein G, Bernadt M, Katona CL. Outcome in refractory depression. J Affect Disord. 1999;54:287–94.
   PubMed Web of Science ®Google Scholar
• O'Leary DA, Lee AS. Seven year prognosis in depression. Mortality and readmission risk in the Nottingham ECT cohort. Br J Psychiatry. 1996;169:423–9.
   PubMed Web of Science ®Google Scholar
• Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry. 2007; 52:46–54.
   PubMed Web of Science ®Google Scholar
• Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58 Suppl 13:23–9.
   Web of Science ®Google Scholar
• Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, . Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9:83–91.
   PubMed Web of Science ®Google Scholar
• Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry. 2001;62 Suppl 16:26–31.
   Web of Science ®Google Scholar
• Souery D, Lipp O, Massat I, Mendlewicz J. The characterization and definition of treatment-resistant mood disorders. Amsterdam JD, Hornig M, Nierenberg AA. Treatment-resistant mood disorders. New York: Cambridge University Press; 2001. 3–29.
   Google Scholar
• Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, ; Group for the Study of Resistant Depression. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68:1062–70.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, ; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.
   PubMed Web of Science ®Google Scholar
• Martinez-Arán A, Vieta E, Chengappa KN, Gershon S, Mullen J, Paulsson B. Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change. Bipolar Disord. 2008;10:566–79.
   PubMed Web of Science ®Google Scholar
• Sachs GS. Treatment-resistant bipolar depression. Psychiatr Clin North Am. 1996;19:215–36.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Calabrese JR, Kusumakar V. Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord. 2003;5:85–97.
   PubMed Web of Science ®Google Scholar
• Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry. 2006;11:227–40.
   PubMed Web of Science ®Google Scholar
• Weisler RH, Calabrese JR, Thase ME, Arvekvist R, Stening G, Paulsson B, . Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry. 2008;69:769–82.
   PubMed Web of Science ®Google Scholar
• Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, ; EMBOLDEN I (Trial 001) Investigators. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010;71:150–62.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, ; EMBOLDEN II (Trial D1447C00134) Investigators. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71:163–74.
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, . Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60:1079–88.
   PubMed Web of Science ®Google Scholar
• Tohen M, Case M, Trivedi MH, Thase ME, Burke SJ, Durell TM. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry. 2010;71:451–62.
   PubMed Web of Science ®Google Scholar
• Thase ME, MacFadden W, Weisler RH, Chang W, Paulsson B, Khan A, . Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26:600–9.
   PubMed Web of Science ®Google Scholar
• Berk M, Ng F, Wang WV, Calabrese JR, Mitchell PB, Malhi GS, . The empirical redefinition of the psychometric criteria for remission in bipolar disorder. J Affect Disord. 2008;106:153–8.
   PubMed Web of Science ®Google Scholar
• Ustün TB, Kessler RC. Global burden of depressive disorders: the issue of duration. Br J Psychiatry. 2002;181: 181–3.
   PubMed Web of Science ®Google Scholar
• Mueller TI, Keller MB, Leon AC, Solomon DA, Shea MT, Coryell W, . Recovery after 5 years of unremitting major depressive disorder. Arch Gen Psychiatry. 1996;53: 794–9.
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, White K. What next? A review of pharmacologic strategies for treatment resistant depression. Psychopharmacol Bull. 1990;26:429–60.
   PubMedGoogle Scholar
• Dunner DL, Rush AJ, Russell JM, Burke M, Woodard S, Wingard P, . Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry. 2006;67:688–95.
   PubMed Web of Science ®Google Scholar
• Vieta E, Nieto E, Autet A, Rosa AR, Goikolea JM, Cruz N, . A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World J Biol Psychiatry. 2008;9:219–24.
   PubMed Web of Science ®Google Scholar
• Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25: 1171–80.
   PubMed Web of Science ®Google Scholar
• Kennedy N, Abbott R, Paykel ES. Longitudinal syndromal and sub-syndromal symptoms after severe depression: 10-year follow-up study. Br J Psychiatry. 2004;184:330–6.
   PubMed Web of Science ®Google Scholar
• Fekadu A, Wooderson SC, Markopoulou K, Cleare AJ. The Maudsley staging method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms. J Clin Psychiatry. 2009;70:952–7.
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Rosenquist KJ, Ko JY, Baldassano CF, Kontos NJ, Baldessarini RJ. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry. 2004; 161:163–5.
   PubMed Web of Science ®Google Scholar
• Pacchiarotti I, Valentí M, Bonnin CM, Rosa AR, Murru A, Kotzalidis GD, . Factors associated with initial treatment response with antidepressants in bipolar disorder. Eur Neuropsychopharmacol. 2011;21:362–9.
   PubMed Web of Science ®Google Scholar
• Adli M, Berghöfer A, Linden M, Helmchen H, Müller-Oerlinghausen B, Mackert A, . Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study. J Clin Psychiatry. 2002;63:782–90.
   PubMed Web of Science ®Google Scholar
• Adli M, Bauer M, Rush AJ. Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. Biol Psychiatry. 2006;59:1029–38.
   PubMed Web of Science ®Google Scholar
• Adli M, Rush AJ, Möller HJ, Bauer M. Algorithms for optimizing the treatment of depression: making the right decision at the right time. Pharmacopsychiatry. 2003;36 Suppl 3:S222–9.
   PubMedGoogle Scholar
• Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, . Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry. 2004;61:669–80.
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010;18:143–57.
   PubMed Web of Science ®Google Scholar
• Mitchell PB, Malhi GS. Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Disord. 2004;6:530–9.
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck PE Jr, . Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000;157: 1873–5.
   PubMed Web of Science ®Google Scholar
• Kiejna A, Pawłowski T, Dudek D, Lojko D, Siwek M, Roczeń R, . The utility of Mood Disorder Questionnaire for the detection of bipolar diathesis in treatment-resistant depression. J Affect Disord. 2010;124:270–4.
   PubMed Web of Science ®Google Scholar
• Mischoulon D, Nierenberg AA, Kizilbash L, Rosenbaum JF, Fava M. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry. 2000;45:476–81.
   PubMed Web of Science ®Google Scholar
• Shergill SS, Katona CL. Pharmacological choices after one antidepressant fails: a survey of UK psychiatrists. J Affect Disord. 1997;43:19–25.
   PubMed Web of Science ®Google Scholar
• Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2005;255:387–4.
   PubMed Web of Science ®Google Scholar
• Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, ; Arbeitsge-meinschaft fur neuropsychopharmakologie und pharmakopsychiatrie. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243–65.
   PubMed Web of Science ®Google Scholar
• Pridmore S, Turnier-Shea Y. Medication options in the treatment of treatment-resistant depression. Aust N Z J Psychiatry. 2004;38:219–25.
   PubMed Web of Science ®Google Scholar
• Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom. 2006;75:139–53.
   PubMed Web of Science ®Google Scholar
• Davidson J, McLeod M, Law-Yone B, Linnoila M. A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Arch Gen Psychiatry. 1978;35:639–42.
   PubMed Web of Science ®Google Scholar
• Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994; 151:1372–4.
   PubMed Web of Science ®Google Scholar
• Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, . Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol. 2002;22:379–87.
   PubMed Web of Science ®Google Scholar
• Perlis RH, Iosifescu DV, Alpert J, Nierenberg AA, Rosenbaum JF, Fava M. Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. Psychosomatics. 2004;45:224–9.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry. 2004;55: 296–300.
   PubMed Web of Science ®Google Scholar
• Joffe RT, MacQueen GM, Marriott M, Young LT. One-year outcome with antidepressant—treatment of bipolar depression. Acta Psychiatr Scand. 2005;112:105–9.
   PubMed Web of Science ®Google Scholar
• Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord. 1996;41:201–10.
   PubMed Web of Science ®Google Scholar
• Ferreri M, Lavergne F, Berlin I, Payan C, Puech AJ. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand. 2001;103:66–72.
   PubMed Web of Science ®Google Scholar
• Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl). 2002;161:143–51.
   PubMed Web of Science ®Google Scholar
• Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry. 1999;60:45–9.
   PubMed Web of Science ®Google Scholar
• Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002;51:183–8.
   PubMed Web of Science ®Google Scholar
• McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, . Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;163:1531–41.
   PubMed Web of Science ®Google Scholar
• Berlanga C, Ortega-Soto HA. A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. J Affect Disord. 1995;34: 187–92.
   PubMed Web of Science ®Google Scholar
• König F, Wolfersdorf M. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression. Pharmacopsychiatry. 1997;30:93–6.
   PubMed Web of Science ®Google Scholar
• Joffe RT, Bakish D. Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatry. 1994;55:24–5.
   PubMed Web of Science ®Google Scholar
• Hawley CJ, Quick SJ, Ratnam S, Pattinson HA, McPhee S. Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients. Int Clin Psychopharmacol. 1996;11:187–91.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, García-España F, Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. Depress Anxiety. 1997;5:84–90.
   PubMedGoogle Scholar
• Lam RW, Hossie H, Solomons K, Yatham LN. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry. 2004;65:337–40.
   PubMed Web of Science ®Google Scholar
• Lucca A, Serretti A, Smeraldi E. Effect of reboxetine augmentation in SSRI resistant patients. Hum Psychopharmacol. 2000;15:143–5.
   PubMed Web of Science ®Google Scholar
• Harkin A, Nally R, Kelly JP, Leonard BE. Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and beta1-adrenergic receptors in an animal model of depression. J Neural Transm. 2000;107:1213–27.
   PubMed Web of Science ®Google Scholar
• Rubio G, San L, López-Munoz F, García-García P, Alamo C. Combination therapy with reboxetine for major depression patients who are partial or nonresponders to serotonin selective reuptake inhibitors. Actas Esp Psiquiatr. 2003;31:315–24.
   PubMed Web of Science ®Google Scholar
• Rubio G, San L, López-Muñoz F, Alamo C. Reboxetine adjunct for partial or nonresponders to antidepressant treatment. J Affect Disord. 2004;81:67–72.
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007;68:826–31.
   PubMed Web of Science ®Google Scholar
• Thase ME, Rush AJ, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ, . Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry. 2002;59: 233–9.
   PubMed Web of Science ®Google Scholar
• Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J, . Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry. 2001;62:413–20.
   PubMed Web of Science ®Google Scholar
• Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry. 1999;175:12–16.
   PubMed Web of Science ®Google Scholar
• Bschor T, Baethge C. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand. 2010; 121:174–9.
   PubMed Web of Science ®Google Scholar
• Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ; World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry. 2002;3:5–43.
   PubMedGoogle Scholar
• Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ; World Federation of Societies of Biological Psychiatry (WFSBF) Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry. 2002;3:69–86.
   PubMedGoogle Scholar
• Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry. 1993;162: 634–40.
   PubMed Web of Science ®Google Scholar
• Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, . A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol. 1996;16:307–14.
   PubMed Web of Science ®Google Scholar
• Joffe RT. Treating mood disorders. J Psychiatry Neurosci. 2003;28:9–10.
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Papakostas GI, Petersen T, Montoya HD, Worthington JJ, Tedlow J, . Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol. 2003;23:92–5.
   PubMed Web of Science ®Google Scholar
• Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007;68:935–40.
   PubMed Web of Science ®Google Scholar
• Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994;151: 1372–4.
   PubMed Web of Science ®Google Scholar
• Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007;68:935–40.
   PubMed Web of Science ®Google Scholar
• Gutierrez RL, McKercher RM, Galea J, Jamison KL. Lamotrigine augmentation strategy for patients with treatment-resistant depression. CNS Spectr. 2005;10: 800–5.
   PubMed Web of Science ®Google Scholar
• Barbee JG, Jamhour NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry. 2002;63:737–41.
   PubMed Web of Science ®Google Scholar
• Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003;64:403–7.
   PubMed Web of Science ®Google Scholar
• Santos MA, Rocha FL, Hara C. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Prim Care Companion J Clin Psychiatry. 2008;10:187–90.
   PubMedGoogle Scholar
• Joffe R, Nobrega J, Kish S, Calvo R, Dixon L, Wilson J. Desipramine reduces plasma but not brain thyroxine levels. Biol Psychiatry. 1993;33:293–4.
   PubMed Web of Science ®Google Scholar
• Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 1996;53:842–8.
   PubMed Web of Science ®Google Scholar
• Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry. 2001;62:448–52.
   PubMed Web of Science ®Google Scholar
• Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, . The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68:843–53.
   PubMed Web of Science ®Google Scholar
• Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, . Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14:197–206.
   PubMed Web of Science ®Google Scholar
• Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, . The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008; 28:156–65.
   PubMed Web of Science ®Google Scholar
• Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, . A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158: 131–4.
   PubMed Web of Science ®Google Scholar
• Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, . A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68:224–36.
   PubMed Web of Science ®Google Scholar
• Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, . Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry. 2005;66:1289–97.
   PubMed Web of Science ®Google Scholar
• Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety. 2006;23:364–72.
   PubMed Web of Science ®Google Scholar
• Bobo WV, Shelton RC. Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues. Neuropsychiatr Dis Treat. 2009;5:369–83.
   PubMed Web of Science ®Google Scholar
• Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, . Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med. 2007;147:593–602.
   PubMed Web of Science ®Google Scholar
• Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, . A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res. 2009;43:205–14.
   PubMed Web of Science ®Google Scholar
• Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69:1228–336.
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, . Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology. 2006;31: 2505–13.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166:980–91.
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Worthington JJ 3rd, Iosifescu DV, Kinrys G, Burns AM, Fisher LB, . The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety. 2006;23:178–81.
   PubMed Web of Science ®Google Scholar
• Inoue T, Tsuchiya K, Miura J, Sakakibara S, Denda K, Kasahara T, . Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry. 1996;40:151–3.
   PubMed Web of Science ®Google Scholar
• Izumi T, Inoue T, Kitagawa N, Nishi N, Shimanaka S, Takahashi Y, . Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J Affect Disord. 2000;61:127–32.
   PubMed Web of Science ®Google Scholar
• Sporn J, Ghaemi SN, Sambur MR, Rankin MA, Recht J, Sachs GS, . Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry. 2000;12:137–40.
   PubMedGoogle Scholar
• Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR, . Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord. 2002;4: 307–14.
   PubMed Web of Science ®Google Scholar
• Cassano P, Lattanzi L, Fava M, Navari S, Battistini G, Abelli M, . Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry. 2005;50: 357–60.
   PubMed Web of Science ®Google Scholar
• Inoue T, Kitaichi Y, Masui T, Nakagawa S, Boku S, Tanaka T, . Pramipexole for stage 2 treatment-resistant major depression: An open study. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:1446–9.
   PubMed Web of Science ®Google Scholar
• Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, . A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006;26:653–6.
   PubMed Web of Science ®Google Scholar
• Ravindran AV, Kennedy SH, O'Donovan MC, Fallu A, Camacho F, Binder CE. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2008;69:87–94.
   PubMed Web of Science ®Google Scholar
• Michelson D, Adler LA, Amsterdam JD, Dunner DL, Nierenberg AA, Reimherr FW, . Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68:582–7.
   PubMed Web of Science ®Google Scholar
• Dunlop BW, Crits-Christoph P, Evans DL, Hirschowitz J, Solvason HB, Rickels K, . Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007;27:614–9.
   PubMed Web of Science ®Google Scholar
• Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005;66: 85–93.
   PubMed Web of Science ®Google Scholar
• Pérez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 1997;349:1594–7.
   PubMed Web of Science ®Google Scholar
• Moreno FA, Gelenberg AJ, Bachar K, Delgado PL. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry. 1997;58:437–9.
   PubMed Web of Science ®Google Scholar
• Portella MJ, de Diego-Adeliño J, Ballesteros J, Puigdemont D, Oller S, Santos B, . Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry. 2010 Oct 19 (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Perry EB, Berman RM, Sanacora G, Anand A, Lynch-Colonese K, Charney DS. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. J Clin Psychiatry. 2004;65:238–43.
   PubMed Web of Science ®Google Scholar
• Pérez V, Soler J, Puigdemont D, Alvarez E, Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch Gen Psychiatry. 1999;56:375–9.
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Emsley R, Rembry S, Rouillon F. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70:1128–37.
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Bauer VK, Cutler NL, Sack RL. Melatonin treatment of winter depression: a pilot study. Psychiatry Res. 1998;77:57–61.
   PubMed Web of Science ®Google Scholar
• Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63: 1121–9.
   PubMed Web of Science ®Google Scholar
• George TP, Sacco KA, Vessicchio JC, Weinberger AH, Shytle RD. Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. J Clin Psychopharmacol. 2008;28:340–4.
   PubMed Web of Science ®Google Scholar
• Sato Y, Yasui-Furukori N, Nakagami T, Saito M, Kaneko S. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33: 416–8.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, . A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163:153–5.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, . A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–64.
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008;28:631–7.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, . Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry. 2007;61:822–5.
   PubMed Web of Science ®Google Scholar
• Rogóz Z, Skuza G, Daniel WA, Wójcikowski J, Dudek D, Wróbel A. Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacol Rep. 2007;59:778–84.
   PubMed Web of Science ®Google Scholar
• UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361:799–808.
   PubMed Web of Science ®Google Scholar
• Pearlman C. Electroconvulsive therapy in clinical psychopharmacology. J Clin Psychopharmacol. 2002;22:345–6.
   PubMed Web of Science ®Google Scholar
• Folkerts HW, Michael N, Tolle R, Schonauer K, Mucke S, Schulze-Monking H. Electroconvulsive therapy vs. paroxetine in treatment-resistant depression—a randomized study. Acta Psychiatr Scand. 1997;96:334–42.
   PubMed Web of Science ®Google Scholar
• Khalid N, Atkins M, Tredget J, Giles M, Champney-Smith K, Kirov G. The effectiveness of electroconvulsive therapy in treatment-resistant depression: a naturalistic study. J ECT. 2008;24:141–5.
   PubMed Web of Science ®Google Scholar
• Lisanby SH, Schlaepfer TE, Fisch HU, Sackeim HA. Magnetic seizure therapy of major depression. Arch Gen Psychiatry. 2001;58:303–5.
   PubMed Web of Science ®Google Scholar
• Kayser S, Bewernick BH, Grubert C, Hadrysiewicz BL, Axmacher N, Schlaepfer TE. Antidepressant effects, of magnetic seizure therapy and electroconvulsive therapy, in treatment-resistant depression. J Psychiatr Res. 2011;45: 569–76.
   PubMed Web of Science ®Google Scholar
• Rush AJ, George MS, Sackeim HA, Marangell LB, Husain MM, Giller C, . Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry. 2000;47:276–86.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Sackeim HA, Marangell LB George MS, Brannan SK, Davis SM, . Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry. 2005;58:355–63.
   PubMed Web of Science ®Google Scholar
• Sackeim HA, Rush AJ, George MS, Marangell LB, Husain MM, Nahas Z, . Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001;25:713–28.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, . Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005;58:347–54.
   PubMed Web of Science ®Google Scholar
• Henry TR, Bakay RA, Pennell PB, Epstein CM, Votaw JR. Brain blood-flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: II. Prolonged effects at high and low levels of stimulation. Epilepsia. 2004;45: 1064–70.
   PubMed Web of Science ®Google Scholar
• Daban C, Martinez-Aran A, Cruz N, Vieta E. Safety and efficacy of vagus nerve stimulation in treatment-resistant depression. A systematic review. J Affect Disord. 2008;110: 1–15.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, . Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry. 2005;58:355–63.
   PubMed Web of Science ®Google Scholar
• Nahas Z, Marangell LB, Husain MM, Rush AJ, Sackeim HA, Lisanby SH, . Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry. 2005;66:1097–104.
   PubMed Web of Science ®Google Scholar
• George MS, Rush AJ, Marangell LB, Sackeim HA, Brannan SK, Davis SM, . A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry. 2005;58: 364–73.
   PubMed Web of Science ®Google Scholar
• Bajbouj M, Merkl A, Schlaepfer TE, Frick C, Zobel A, Maier W, . Two-year outcome of vagus nerve stimulation in treatment-resistant depression. J Clin Psychopharmacol. 2010;30:273–81.
   PubMed Web of Science ®Google Scholar
• Loo CK, Mitchell PB. A review of the efficacy of transcranial magnetic stimulation (TMS) treatment for depression, and current and future strategies to optimize efficacy. J Affect Disord. 2005;88:255–67.
   PubMed Web of Science ®Google Scholar
• Herrmann LL, Ebmeier KP. Factors modifying the efficacy of transcranial magnetic stimulation in the treatment of depression: a review. J Clin Psychiatry. 2006;67:1870–6.
   PubMed Web of Science ®Google Scholar
• Daskalakis ZJ, Levinson AJ, Fitzgerald PB. Repetitive transcranial magnetic stimulation for major depressive disorder: a review. Can J Psychiatry. 2008;53:555–66.
   PubMed Web of Science ®Google Scholar
• George MS, Wassermann EM, Williams WA, Callahan A, Ketter TA, Basser P, . Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport. 1995;6:1853–6.
   PubMed Web of Science ®Google Scholar
• George MS, Nahas Z, Molloy M, Speer AM, Oliver NC, Li XB, . A controlled trial of daily left prefrontal cortex TMS for treating depression. Biol Psychiatry. 2000;48: 962–70.
   PubMed Web of Science ®Google Scholar
• Padberg F, George MS. Repetitive transcranial magnetic stimulation of the prefrontal cortex in depression. Exp Neurol. 2009;219:2–13.
   PubMed Web of Science ®Google Scholar
• Berman RM, Narasimhan M, Sanacora G, Miano AP, Hoffman RE, Hu XS, . A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biol Psychiatry. 2000;47: 332–7.
   PubMed Web of Science ®Google Scholar
• Grunhaus L, Schreiber S, Dolberg OT, Polak D, Dannon PN. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. Biol Psychiatry. 2003;53:324–31.
   PubMed Web of Science ®Google Scholar
• Fitzgerald PB, Huntsman S, Gunewardene R, Kulkarni J, Daskalakis ZJ. A randomized trial of low-frequency right-prefrontal-cortex transcranial magnetic stimulation as augmentation in treatment-resistant major depression. Int J Neuropsychopharmacol. 2006;9:655–66.
   PubMed Web of Science ®Google Scholar
• McNamara B, Ray JL, Arthurs OJ, Boniface S. Transcranial magnetic stimulation for depression and other psychiatric disorders. Psychol Med. 2001;31:1141–6.
   PubMed Web of Science ®Google Scholar
• Burt T, Lisanby SH, Sackeim HA. Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. Int J Neuropsychopharmacol. 2002;5:73–103.
   PubMed Web of Science ®Google Scholar
• Lam RW, Chan P, Wilkins-Ho M, Yatham LN. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and metaanalysis. Can J Psychiatry. 2008;53:621–31.
   PubMed Web of Science ®Google Scholar
• Fitzgerald PB, Hoy K, Gunewardene R, Slack C, Ibrahim S, Bailey M, . A randomized trial of unilateral and bilateral prefrontal cortex transcranial magnetic stimulation in treatment-resistant major depression. Psychol Med. 2010:1–10.
   Web of Science ®Google Scholar
• Holtzheimer PE, McDonald WM, Mufti M, Kelley ME, Quinn S, Corso G, . Accelerated repetitive transcranial magnetic stimulation for treatment-resistant depression. Depress Anxiety. 2010;27:960–3.
   PubMed Web of Science ®Google Scholar
• Bretlau LG, Lunde M, Lindberg L, Undén M, Dissing S, Bech P. Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial. Pharmacopsychiatry. 2008;41:41–7.
   PubMed Web of Science ®Google Scholar
• Berlim MT, McGirr A, Beaulieu MM, Turecki G. High frequency repetitive transcranial magnetic stimulation as an augmenting strategy in severe treatment-resistant major depression: A prospective 4-week naturalistic trial. J Affect Disord. 2011;130:312–7.
   PubMed Web of Science ®Google Scholar
• Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, . Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45: 651–60.
   PubMed Web of Science ®Google Scholar
• Pallanti S, Bernardi S, Di Rollo A, Antonini S, Quercioli L. Unilateral low frequency versus sequential bilateral repetitive transcranial magnetic stimulation: is simpler better for treatment of resistant depression? Neuroscience. 2010;167:323–8.
   PubMed Web of Science ®Google Scholar
• Lakhan SE, Callaway E. Deep brain stimulation for obsessive-compulsive disorder and treatment-resistant depression: systematic review. BMC Res Notes. 2010;3: 60.
   PubMedGoogle Scholar
• Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, . Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45: 651–60.
   PubMed Web of Science ®Google Scholar
• Schlaepfer TE, Lieb K. Deep brain stimulation for treatment of refractory depression. Lancet. 2005;366:1420–2.
   PubMed Web of Science ®Google Scholar
• Jiménez F, Velasco F, Salín-Pascual R, Velasco M, Nicolini H, Velasco AL, . Neuromodulation of the inferior thalamic peduncle for major depression and obsessive compulsive disorder. Acta Neurochir Suppl. 2007; 97(Pt 2):393–8.
   PubMedGoogle Scholar
• Lozano AM, Mayberg HS, Giacobbe P, Hamani C, Craddock RC, Kennedy SH. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry. 2008;64:461–7.
   PubMed Web of Science ®Google Scholar
• Malone DA Jr, Dougherty DD, Rezai AR, Carpenter LL, Friehs GM, Eskandar EN, . Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry. 2009;65:267–75.
   PubMed Web of Science ®Google Scholar
• Wang X, Chang C, Geng N, Li N, Wang J, Ma J, . Long-term effects of bilateral deep brain stimulation of the subthalamic nucleus on depression in patients with Parkinson's disease. Parkinsonism Relat Disord. 2009;15: 587–91.
   PubMed Web of Science ®Google Scholar
• Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF, . Cognitive therapy versus medication in augmentation and switch strategies as secondstep treatments: a STAR*D report. Am J Psychiatry. 2007;164:739–52.
   PubMed Web of Science ®Google Scholar
• Scott J, Teasdale J, Paykel E, Johnson A, Abbott R, Hayhurst H, . Effects of cognitive therapy on psychological symptoms and social functioning in residual depression. Br J Psychiatry. 2000;177:440–6.
   PubMed Web of Science ®Google Scholar
• Matsunaga M, Okamoto Y, Suzuki S, Kinoshita A, Yoshimura S, Yoshino A, . Psychosocial functioning in patients with treatment-resistant depression after group cognitive behavioral therapy. BMC Psychiatry. 2010; 10:22.
   PubMed Web of Science ®Google Scholar
• Vieta E, Locklear J, Günther O, Ekman M, Miltenburger C, Chatterton ML, . Treatment options for bipolar depression: a systematic review of randomized, controlled trials. J Clin Psychopharmacol. 2010;30:579–90.
   PubMed Web of Science ®Google Scholar
• International consensus group on the evidence-based pharmachologic treatment of bipolar I and II depression. J Clin Psychiatry. 2008;69:1632–46.
   PubMedGoogle Scholar
• Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, . Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11:225–55.
   PubMed Web of Science ®Google Scholar
• Gitlin MJ, Abulseoud O, Frye MA. Improving the design of maintenance studies for bipolar disorder. Curr Med Res Opin. 2010;26:1835–42.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, . Guidelines Group, CANMAT. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006;8:721–39.
   PubMed Web of Science ®Google Scholar
• Goldberg JF. Optimizing treatment outcomes in bipolar disorder under ordinary conditions. J Clin Psychiatry. 2008;69(suppl3):11–19.
   PubMedGoogle Scholar
• Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, . Efficacy of olanzapine and olanzapine–fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60:1079–88.
   PubMed Web of Science ®Google Scholar
• Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valentí M, Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol. 2010;13:5–14.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, . A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162: 1351–60.
   PubMed Web of Science ®Google Scholar
• Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, ; BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26:600–9.
   Google Scholar
• Frye MA, Grunze H, Suppes T, McElroy SL, Keck PE Jr, Walden J, . A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164:1242–9.
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161:564–66.
   PubMed Web of Science ®Google Scholar
• Nolen WA, Kupka RW, Hellemann G, Frye MA, Altshuler LL, Leverich GS, . Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand. 2007;115:360–5.
   PubMed Web of Science ®Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, . A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67: 793–802.
   PubMed Web of Science ®Google Scholar
• Van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, ; LamLit Study Group. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70:223–31.
   Google Scholar
• Van der Loos ML, Mulder P, Hartong EG, Blom MB, Vergouwen AC, van Noorden MS, ; LamLit Study Group. Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatr Scand. 2010;122:246–54.
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, . Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006; 163:210–6.
   PubMed Web of Science ®Google Scholar
• Nierenberg AA. Low-dose buspirone, melatonin and low-dose bupropion added to mood stabilizers for severe treatment-resistant bipolar depression. Psychother Psychosom. 2009;78:391–3.
   PubMed Web of Science ®Google Scholar
• Kelly T, Lieberman DZ. The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS. J Affect Disord. 2009;116:222–6.
   PubMed Web of Science ®Google Scholar
• Kemp DE, Dago PL, Straus JL, Fleck J, Karaffa M, Gilmer WS. Aripiprazole augmentation for treatment-resistant bipolar depression: sustained remission after 36 months. J Clin Psychopharmacol. 2007;27:304–5.
   PubMed Web of Science ®Google Scholar
• Ketter TA, Wang PW, Chandler RA, Culver JL, Alarcon AM. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann Clin Psychiatry. 2006;18:169–72.
   PubMedGoogle Scholar
• Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, ; WFSBP Task Force On Treatment Guidelines For Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11:81–109.
   Google Scholar
• Goodwin GM; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition— recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23:346–88.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, . Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11:225–55.
   PubMed Web of Science ®Google Scholar
• Valenti M, Benabarre A, Bernardo M, García-Amador M, Amann B, Vieta E. [Electroconvulsive therapy in the treatment of bipolar depression]. Actas Esp Psiquiatr. 2007; 35:199–207.
   PubMed Web of Science ®Google Scholar
• Daly JJ, Prudic J, Devanand DP, Nobler MS, Lisanby SH, Peyser S, . ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disord. 2001;3: 95–104.
   PubMed Web of Science ®Google Scholar
• Kessler U, Vaaler AE, Schøyen H, Oedegaard KJ, Bergsholm P, Andreassen OA, . The study protocol of the Norwegian randomized controlled trial of electroconvulsive therapy in treatment resistant depression in bipolar disorder. BMC Psychiatry. 2010;10:16.
   PubMed Web of Science ®Google Scholar
• Daban C, Martinez-Aran A, Cruz N, Vieta E. Safety and efficacy of vagus nerve stimulation in treatment-resistant depression. A systematic review. J Affect Disord. 2008; 110:1–15.
   PubMed Web of Science ®Google Scholar
• Nierenberg AA. Predictors of response to antidepressants general principles and clinical implications. Psychiatr Clin North Am. 2003;26:345–52.
   PubMed Web of Science ®Google Scholar